[go: up one dir, main page]

MX2023012170A - Metodos y materiales para detectar polipeptidos mal plegados. - Google Patents

Metodos y materiales para detectar polipeptidos mal plegados.

Info

Publication number
MX2023012170A
MX2023012170A MX2023012170A MX2023012170A MX2023012170A MX 2023012170 A MX2023012170 A MX 2023012170A MX 2023012170 A MX2023012170 A MX 2023012170A MX 2023012170 A MX2023012170 A MX 2023012170A MX 2023012170 A MX2023012170 A MX 2023012170A
Authority
MX
Mexico
Prior art keywords
sample
materials
methods
misfolded polypeptides
absence
Prior art date
Application number
MX2023012170A
Other languages
English (en)
Inventor
Peter Christenson
Gage Rowden
Sang- Hyun OH
Peter Anthony Larsen
Manci Li
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MX2023012170A publication Critical patent/MX2023012170A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587Nanoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2828Prion diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Este documento se refiere a métodos y materiales para detectar la presencia o ausencia de polipéptidos mal plegados en una muestra. Por ejemplo, se proporcionan métodos y materiales para amplificar una muestra (por ejemplo, una muestra biológica o una muestra ambiental) de modo que los polipéptidos mal plegados presentes en la muestra puedan agregarse para formar fibrillas y/o agregados de polipéptidos globulares y poner en contacto la muestra amplificada con una solución que contiene nanopartículas metálicas (por ejemplo, nanopartículas de oro) o uno o más colorantes orgánicos (por ejemplo, rojo Congo) para detectar la presencia o ausencia de fibrillas y/o agregados de polipéptidos globulares. En algunos casos, se proporcionan métodos y materiales para determinar si un mamífero (por ejemplo, un ser humano) tiene una proteinopatía basada, al menos en parte, en la presencia o ausencia de polipéptidos mal plegados en una muestra obtenida del mamífero.
MX2023012170A 2021-04-16 2022-04-15 Metodos y materiales para detectar polipeptidos mal plegados. MX2023012170A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176114P 2021-04-16 2021-04-16
US202163277999P 2021-11-10 2021-11-10
PCT/US2022/025059 WO2022221683A1 (en) 2021-04-16 2022-04-15 Methods and materials for detecting misfolded polypeptides

Publications (1)

Publication Number Publication Date
MX2023012170A true MX2023012170A (es) 2024-01-09

Family

ID=83640898

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012170A MX2023012170A (es) 2021-04-16 2022-04-15 Metodos y materiales para detectar polipeptidos mal plegados.

Country Status (6)

Country Link
US (1) US20240192229A1 (es)
EP (1) EP4323773A4 (es)
KR (1) KR20230170958A (es)
CA (1) CA3216826A1 (es)
MX (1) MX2023012170A (es)
WO (1) WO2022221683A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220662A2 (en) * 2023-04-18 2024-10-24 Regents Of The University Of Minnesota Nanoparticle enhanced methods and materials for detecting misfolded polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002001230A2 (en) * 2000-06-23 2002-01-03 Minerva Biotechnologies Corporation Rapid and sensitive detection of protein aggregation
US8298793B2 (en) * 2002-09-30 2012-10-30 Auburn University Methods for isolating proteons from plasma samples
EP2074222A4 (en) * 2006-09-06 2010-03-03 Univ Texas METHOD AND COMPOSITIONS FOR DETECTING PROTEIN DISORDERING
WO2016123401A1 (en) * 2015-01-28 2016-08-04 University Of Delaware Detection of disease-associated tau protein conformations and applications thereof

Also Published As

Publication number Publication date
WO2022221683A1 (en) 2022-10-20
EP4323773A1 (en) 2024-02-21
KR20230170958A (ko) 2023-12-19
CA3216826A1 (en) 2022-10-20
US20240192229A1 (en) 2024-06-13
EP4323773A4 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
KR101808872B1 (ko) 검체 중의 측정 대상 성분의 측정 방법 및 측정용 키트
ATE556030T1 (de) Ultrasensitiver nachweis von analyten
IL188460A0 (en) Diagnostic methods and compositions for diagnosing and treating influenza
MX2023012170A (es) Metodos y materiales para detectar polipeptidos mal plegados.
Rosen et al. Cohesin cleavage by separase is enhanced by a substrate motif distinct from the cleavage site
CN104861073A (zh) 检测mmp-13活性的fret融合荧光探针、检测方法、dna和表达载体
Lou et al. Quick and sensitive SPR detection of prion disease-associated isoform (PrPSc) based on its self-assembling behavior on bare gold film and specific interactions with aptamer-graphene oxide (AGO)
Datki et al. Application of BisANS fluorescent dye for developing a novel protein assay
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE337553T1 (de) Fluoreszenzintenstitätsmethode zur bestimmung der bindung zwischen proteinen oder peptiden
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
Koterwa et al. An electrochemical biosensor for the determination of hormone Human Chorionic Gonadotropin (hCG) in human serum
Sun et al. Ion monitoring at nanoscale sites of interorganelle membrane contact in living cells
SG10201806697RA (en) Method for detecting basophil activation
WO2024220662A3 (en) Nanoparticle enhanced methods and materials for detecting misfolded polypeptides
ES2530574T3 (es) Biomarcadores asociados a la nefropatía
Jin et al. A label-free fluorescence assay for thrombin activity analysis based on fluorescent protein and gold nanoparticles
JP2007225603A (ja) 試料中の測定対象物の免疫測定方法および免疫測定試薬
US20180188233A1 (en) Biological assay of peptidoglycans
Shen et al. Genetically encoded ratiometric indicators for potassium ion
CN109983133A (zh) 用于分析受体-配体Koff速率的可逆和不可逆细胞标记的组合
Kim et al. One label-based fluorescence detection of a protease that cleaves the peptide bond between two specific amino acids
Meyers et al. A cell-based assay for rapid assessment of ACE2 catalytic function
RU2011110344A (ru) Способ обнаружения аналита в микромассиве образцов и устройство для осуществления этого способа
Wang et al. Early diagnosis of myocardial infarction in clinic through CK-MB detection using magnetic separation integrated with chemiluminescence